Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0313540 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Margaret Kypreos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America. Hauptthemen laut MEDLINE: Alveolitis, Extrinsic Allergic, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Treatment of hypersensitivity pneumonitis involves removal of the antigen and may include the use of immunosuppression or antifibrotic therapy. It remains unclear whether antifibrotic or immunosuppressive therapy is more beneficial in fibrotic hypersensitivity pneumonitis or if clinical markers can predict a patient’s response to therapy.
Methods
We evaluated a retrospective cohort in order to determine if certain clinical characteristics can predict physiologic improvement with immunosuppressive treatment in patients with chronic hypersensitivity pneumonitis. Patients with a diagnosis of hypersensitivity pneumonitis with a moderate, high, or definite confidence according to the American Thoracic Society criteria were included in the study.
Results
Overall immunosuppression did not lead to improvement in % predicted forced vital capacity (FVC%) and % predicted diffusion capacity (DLCO%). Patients with fibrotic hypersensitivity pneumonitis and those with familial interstitial lung disease demonstrated a decline in FVC% predicted as well as DLCO% predicted over one year and the use of immunosuppression does not modify that risk. In contrast, patients with extensive ground glass demonstrated improvement in DLCO% predicted but not FVC% predicted over one year with or without the use of immunosuppression.
Conclusion
Our study demonstrates that certain radiographic variables trend toward a significant impact on FVC% predicted as well as DLCO% predicted and suggests that antifibrotic therapy may be a better initial choice of therapy in patients with fibrotic hypersensitivity pneumonitis as decline occurred with or without the use of immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
- Critical Care and Pulmonary Consultants P.C., Greenwood Village, Colorado, United States of America.
- Department of Medical Education, Texas A&M University School of Medicine, Bryan, Texas, United States of America.
ORCID-Profile: Margaret Kypreos, Genichiro Fujioka, Jerry Liu
Zitieren
APA
Kypreos, M., de Boer, E., Ellington, G., Fujioka, G., Liu, J., Glazer, C., & Adams, T. (2024). Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis. PLOS ONE. https://doi.org/10.1371/journal.pone.0313540
Vancouver
Kypreos M, de Boer E, Ellington G, Fujioka G, Liu J, Glazer C, et al. Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis. PLOS ONE. 2024. doi:10.1371/journal.pone.0313540
BibTeX
@article{Kypreos2024,
author = {Kypreos, Margaret and de Boer, Esther and Ellington, Graham and Fujioka, Genichiro and Liu, Jerry and Glazer, Craig and Adams, Traci},
title = {Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0313540}
}
EUVIMED